Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain.
about
alpha-Synuclein and neuronal cell deathThe prion hypothesis in Parkinson's disease: Braak to the futurePhysicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs)At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillationBiochemical characterization of the core structure of alpha-synuclein filaments.The protofilament structure of insulin amyloid fibrils.Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death.Parkinson's disease and other alpha-synucleinopathies.Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model tNeuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.Sumoylation inhibits alpha-synuclein aggregation and toxicity.Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites.Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells.The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors--relevance to Parkinson's disease.Direct Observation of α-Synuclein Amyloid Aggregates in Endocytic Vesicles of Neuroblastoma Cells.Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson diseaseMechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau.Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.α-Synuclein Amyloid Fibrils with Two Entwined, Asymmetrically Associated Protofibrils.Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domainStructure of the toxic core of α-synuclein from invisible crystalsIn vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain.The fold of alpha-synuclein fibrils.Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson diseaseConversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant.Rab11 modulates α-synuclein-mediated defects in synaptic transmission and behaviourSolid-state NMR structure of a pathogenic fibril of full-length human α-synuclein.Applying Hsp104 to protein-misfolding disorders.The Synucleinopathies: Twenty Years On.Parkinson's disease and parkinsonism: neuropathology.Sumoylation in neurodegenerative diseases.The prion hypothesis of Parkinson's disease.The Therapeutic Potential of Cell Identity Reprogramming for the Treatment of Aging-Related Neurodegenerative Disorders.ɑ-Synuclein strains and the variable pathologies of synucleinopathies.Implications of peptide assemblies in amyloid diseases.Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein.Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitroReversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations.Early-onset dementia with Lewy bodies.Structural features of α-synuclein amyloid fibrils revealed by Raman spectroscopy.
P2860
Q21202835-F1064C4E-1BE5-4B36-B413-F6E7C05CDE82Q22001062-F788F79F-4568-4CC2-960B-5F16FEF8A49FQ26823798-13AAFE14-B563-4A90-9431-B98A76655CC4Q30481562-6E1FD7D3-DD4A-4F30-9A0B-A6A38CFC42D2Q30827075-82A5DBF1-4500-41E8-BD69-119634C870BFQ34034361-082F294A-9A8E-45D2-B8FB-E6B862B071A9Q34043163-BCE4FDD7-B6DA-4514-8313-FBED30B01C33Q34270992-F0BE1569-5FC8-4748-B44D-8BA49FC58221Q34321875-A0E5C5E1-2E37-4B69-AD94-33F3506E31D0Q34648491-073FA945-1CEE-46F1-A03D-33638F3FBD9AQ35102441-1CB64EF9-DF07-43B0-A647-44DCB029038CQ35168339-8CD921B9-935A-4838-AEFA-386D7BF6CA5BQ35492403-E55F5089-51F7-4439-BD6A-5B106E28E4CCQ35552497-0F57CF41-480E-41B6-9965-924E0BE9AB91Q35996987-002728FE-7A20-4800-A0F1-D9A81C646442Q36167615-021CF33E-ADA2-4D31-AC57-E64B4D46A944Q36325784-0FE2C35B-093F-4724-8547-1C74D331F5DBQ36454426-19B124A1-06B0-49FA-9817-BA09A11969A9Q36518311-01B379AD-D331-4F86-87B6-52E19947A035Q36527246-1355045C-D0A3-4308-BD70-8ADA19063603Q36685232-5FD614EB-A1E8-4EFA-8D04-918D757CE086Q36691547-3F0EDCDC-ADF8-41E2-96CF-287F85D9352BQ36735295-5E427583-2F2A-4954-BD94-037FBC5D8B27Q36835739-63A899CB-D11D-4D3D-B816-1BD86264609FQ37134437-8D028402-A09E-48DA-B9B3-308F0FB086C3Q37179079-FE564299-1276-4EC9-975C-13B3B2A190F5Q37278078-B30F0394-B9E6-4CC1-A0BB-552074C9841EQ37687090-6529A210-A4C9-4626-A061-CBA3514A0F8BQ37693375-02CDCE2A-C12B-47FC-998E-1CB05B0094C5Q38036232-F19C90EF-4406-41E2-8C23-EBB0B55E0323Q38046126-B1575E42-1503-42F3-9572-78AB71112DF9Q38418624-2BF4A875-95BE-4954-A0A8-79C236D70B5EQ38722713-728978B9-6077-4AA0-B93C-F997619C0036Q38753941-7ED39FC7-4832-498D-AD0D-6A44B2C1B562Q39431937-43D6F53F-D630-417B-9AF9-E7099D837FCBQ40501417-12232B09-6001-4D36-875E-718C36A3659EQ41849419-45C8DE37-6F0A-4FA7-A2F5-7947DAEA6809Q46427562-00455938-E6B3-4BBF-860A-9D75A7C37EA4Q47357514-606E287F-4167-4F0A-AC41-81F6787C5169Q47388669-A840C43A-84F6-4199-A93C-66B9CFD0D902
P2860
Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Characterisation of isolated a ...... of Parkinson's disease brain.
@ast
Characterisation of isolated a ...... of Parkinson's disease brain.
@en
type
label
Characterisation of isolated a ...... of Parkinson's disease brain.
@ast
Characterisation of isolated a ...... of Parkinson's disease brain.
@en
altLabel
Characterisation of isolated α ...... a of Parkinson's disease brain
@en
prefLabel
Characterisation of isolated a ...... of Parkinson's disease brain.
@ast
Characterisation of isolated a ...... of Parkinson's disease brain.
@en
P2093
P921
P1433
P1476
Characterisation of isolated a ...... of Parkinson's disease brain.
@en
P2093
P304
P356
10.1016/S0304-3940(00)01440-3
P407
P577
2000-10-01T00:00:00Z